Michael Grissinger - 16 Jun 2026 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Reporting relationship: Director
Issuer ticker: APRE
Reported as of: 16 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 19:09:50 UTC
Prior SEC filing: 09 Jun 2025
Next SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ John Hamill, as Attorney-in-Fact

Key filing fact

Michael Grissinger filed Form 4 for Aprea Therapeutics, Inc. (APRE) on 17 Jun 2026.

Key facts

This page summarizes Michael Grissinger's Form 4 filing for Aprea Therapeutics, Inc. (APRE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2026, 19:09.

Change

Previous filing in this sequence was filed on 09 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001757601 Primary reporting owner

Grissinger Michael

Relationship: Director
Address: 3805 OLD EASTON ROAD, DOYLESTOWN
Signature: /s/ John Hamill, as Attorney-in-Fact
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APRE transaction

Common Stock

Award

Transaction value
Shares: +3,135
Change %: +109%
Price: $0.000000^*
Shares after: 6,024
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APRE transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +12,555
Change %
Price: $0.000000^*
Shares after: 12,555
Date: 16 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,555
Exercise price: $0.7293
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

Footnote F2

The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.